Why use it

The MELD 3.0 score is the official UNOS liver transplant allocation tool in the United States (adopted 2022). It more accurately predicts 90-day waitlist mortality across sex groups than previous MELD iterations. The score directly determines organ allocation priority and guides timing of transplant listing. It also helps prognosticate in non-transplant settings — e.g., TIPS candidacy, spontaneous bacterial peritonitis outcomes, acute alcoholic hepatitis severity, and post-operative mortality in patients with chronic liver disease.

About

The Model for End-Stage Liver Disease (MELD) score was originally derived by Malinchoc and colleagues in 2000 and adopted by UNOS/OPTN in 2002 as the primary organ allocation tool for liver transplantation in the United States. The MELD score uses serum bilirubin, creatinine, INR, and etiology to estimate 90-day mortality in patients with end-stage liver disease. In 2006, the MELDNa score added serum sodium to improve predictive accuracy. MELD 3.0, published by Kim and colleagues in 2021, is the most current validated iteration. MELD 3.0 corrects a systematic underestimation of waitlist mortality in female patients by incorporating female sex, serum albumin, and serum sodium into the formula, in addition to bilirubin, creatinine, and INR. MELD 3.0 is now the official UNOS allocation formula in the United States as of 2022, replacing the previous MELD-Na formula. Scores range from 6 to 40, with higher scores reflecting higher 90-day mortality and higher transplant priority.

When to use

Liver transplant listing priority and ongoing waitlist monitoring
Estimating 90-day mortality in end-stage liver disease (ESLD)
Determining candidacy for TIPS (transjugular intrahepatic portosystemic shunt)
Prognostication in acute-on-chronic liver failure (ACLF)
Pre-operative risk assessment in patients with cirrhosis undergoing surgery
Monitoring disease progression and guiding intensity of surveillance
Deciding between acute hospitalization and outpatient management in decompensated cirrhosis

Formula

MELD 3.0 = 1.33 × (Female sex: 1=female, 0=male) + 4.56 × ln(Bilirubin mg/dL) + 0.82 × (137 − Sodium mEq/L) − 0.24 × (137 − Sodium mEq/L) × ln(Creatinine mg/dL) + 9.09 × ln(INR) + 11.14 × ln(Creatinine mg/dL) + 1.85 × (3.5 − Albumin g/dL) − 1.83 × (3.5 − Albumin g/dL) × ln(Creatinine mg/dL) + 6 Constraints: Bilirubin, INR: minimum value = 1.0 Creatinine: minimum = 1.0; maximum = 4.0 (dialysis patients = 4.0) Sodium: minimum = 125; maximum = 137 mEq/L Albumin: minimum = 1.5; maximum = 3.5 g/dL Final score: round to nearest integer; minimum = 6; maximum = 40

Pearls & pitfalls

MELD 3.0 replaced MELD-Na as the official UNOS allocation formula in 2022 and provides better equity across sexes by adding female sex as a variable.
Creatinine is capped at 4.0 mg/dL in the formula. Patients on dialysis ≥2× per week are assigned a creatinine of 4.0 mg/dL.
Bilirubin and INR values below 1.0 are set to 1.0 before log transformation to avoid negative numbers.
The MELD score does not account for hepatocellular carcinoma (HCC), hepatopulmonary syndrome, portopulmonary hypertension, or other conditions that receive MELD exception points — these require separate policy-based exceptions.
MELD 3.0 improves female-male equity by adding female sex (+1.33 points) and serum albumin (which is more frequently low in women with ESLD).
A MELD score of ≥15 is typically the threshold above which liver transplantation confers survival benefit over remaining on the waiting list.
MELD score fluctuates with acute events (infection, bleeding, dehydration) and can improve with treatment — reassess after clinical stabilization.
In alcoholic hepatitis, MELD >21 identifies patients likely to benefit from corticosteroid therapy (Maddrey DF >32 is the traditional threshold, but MELD correlates well).
The Child-Pugh score remains clinically useful alongside MELD for assessing functional hepatic reserve (ascites, encephalopathy grades, not captured by MELD).

Next steps

MELD 3.0 <10: Low short-term mortality. Outpatient management appropriate. Optimize underlying liver disease. MELD 3.0 10–18: Moderate risk. Transplant evaluation should be initiated. Monitor every 1–3 months. MELD 3.0 19–24: High mortality risk. Active transplant listing. Careful monitoring for complications (SBP, variceal hemorrhage, HRS, HE). MELD 3.0 ≥25: Very high mortality risk (>50% at 90 days without transplant). Priority listing. Hospitalization for decompensation events. MELD 3.0 ≥40: Extremely high mortality — highest organ allocation priority.

Evidence

Kim WR et al. MELD 3.0: The Model for End-Stage Liver Disease Updated for the 21st Century. Hepatology. 2021;74(3):1347-1363. PMID:33222207. Original MELD: Malinchoc M et al. Hepatology. 2000;31(4):864-871. MELDNa: Kim WR et al. Hepatology. 2008;48(4):1106-1116. UNOS policy adoption of MELD 3.0: effective January 11, 2022.

References

Kim WR et al. MELD 3.0: The Model for End-Stage Liver Disease Updated for the 21st Century. Hepatology. 2021;74(3):1347-1363. — link
Malinchoc M et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864-871. — link
Kim WR et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359(10):1018-1026. — link

MELD Score for End-Stage Liver Disease Mortality (MELD 3.0)

Calculator